Pediatric patients with leukocyte adhesion deficiency type-I (LAD-I) experience severe and recurrent lifethreatening bacterial infections with failure of pus formation and delayed wound healing. LAD-I is a rare inherited disease caused by mutation in the leukocyte CD18 integrin expression, resulting in defective adherence and migration of leukocytes, in particular neutrophilic granulocytes through the intravascular space. Hematopoietic SCT is the only curative treatment option available to patients with LAD-I. Since 2007, in a prospective trial, reduced-intensity conditioning regimen have been developed for 10 consecutive patients with LAD-I who were referred to our center. Based upon available data, it is the first time that such a number of patients affected by LAD-I have been treated with this regimen. This study attempts to show that reduced-intensity regimen leads to a favorable result in LAD-I patients even in those who have experienced comorbid complications. Following transplantation, some patients develop mixed chimerism, however, in our study mixed chimerism was not followed by transplant rejection.
Introduction
Leukocyte adhesion deficiency (LAD) is a rare inherited disorder, first described as a separate entity among the immunodeficiencies in 1979. 1 A deficiency in leukocyte b2-integrin was recognized to be the cause of this syndrome in the early 1980s. Two distinct human disorders of LAD-I and LAD-II have been recognized. [2] [3] [4] LAD-I (the primary focus of our report) is the consequence of a heterogeneous mutation in the leukocyte b2-integrin (CD18) gene, which is located on chromosome 21. The b2-integrin a glycoprotein complex is required for adhesion dependant functions, such as aggregation, chemotaxis, phagocytosis, cell-mediated killing and adherence to vascular endothelium. 5 The severity of clinical presentation and complications in LAD-I correlate with the percentage of leukocytes demonstrating normal CD18 cell surface expression and/or degree of molecule deficiency. Children who suffer a moderate form of the disease have 1-10% normal cell surface expression of CD18, whereas severe LAD-I phenotypes express o1% normal cell surface expression of CD18. 6 Initial presentations include: omphalitis with delayed separation of umbilical cord and overwhelming septicemia. Later on patients develop nonpurulent, recurrent and necrotizing infections of the skin and mucous membranes, as well as persistent leukocytosis, gingivitis and periodontitis. [2] [3] [4] [5] [6] Hematopoietic SCT (HSCT) is the only known curative approach to LAD-I treatment. [6] [7] [8] [9] [10] [11] Reduced intensity and myeloablative conditioning regimens are currently being used in the treatment of patients affected by LAD-I. Although full donor chimerism can be achieved with the use of myeloablative conditioning regimen, this regimen can lead to a higher risk of infections in patients with LAD-I who suffer from comorbid complications. [6] [7] [8] [9] Recent data have shown that reduced-intensity conditioning (RIC) regimen, may lead to establishment of mixed chimerism in humans and canines following HSCT. [8] [9] [10] [11] Despite this known fact, treatment based on RIC regimen because of its low transplant-related morbidity and mortality, has been increasingly utilized in recent years. [11] [12] [13] [14] [15] [16] [17] This study provides evaluation of RIC regimen, utilized in 10 LAD-1 patients who underwent HSCT at Hematology-Oncology and Stem Cell Transplantation research center (HORCSCT). Every single patient in our study, who underwent the same RIC regimen, had variable amounts of chimerism.
Patients and methods

Patient characteristics
This prospective study included 10 pediatric patients with LAD-I. Diagnosis in all patients was confirmed by flow cytometric analysis in peripheral blood cells. In all, 10 patients with LAD-I, who were candidates for HSCT, were referred to the HORCSCT in Shariati Hospital, between January 2007 and September 2009. The median age of patients at the time of transplantation was 2.7 years (range 1-14.7). There were equal number of five girls and five boys. Eight patients had severe type of LAD-I and two had moderate form. The median period from the time of diagnosis of LAD-I to HSCT was 18 months (range 4-105). Various manifestations of the disease, such as: delayed separation of umbilical cord, persistent skin ulcers, gingival and periodontal infections and respiratory tract infections, were frequently observed during the pre-transplant period. Omphalitis and delayed umbilical separation were the most common and significant features. Leukocytosis persistently existed in all of patients from birth. Because of recurrent infections and extensive ulcers, the majority of our patients were admitted multiple times to receive medical treatment and also surgical debridement. However, these treatments seemed ineffective.
Transplant preparation
Adherence to the rules of ethics and protocols were uniformly observed. Signed informed consent by parents of patients was routinely required as a part of the inclusion criteria. A HLA-matched sibling is strongly advocated for donor selection in allogenic HSCT of LAD-I patients. To extend the use of allogeneic HSCT to patients without an HLA-matched sibling donor, we also investigated HSCT from other related donors. Low-resolution molecular typing for HLA-A and -B and -DRB1 were carried out for patients and their sibling. Moreover, high-resolution typing for class-I and II alleles was performed for recipient/ other related donor pairs. Unrelated cord blood stem cell or haplo-identical parent was considered as the last option for the treatment of LAD-I patients.
Transplant procedure
The graft was obtained from one of the three different sources: PBSCs, BM and umbilical cord blood. PBSC were obtained by continuous flow leukopheresis after mobilization by granulocyte CSF (G-CSF) and the BM was harvested under general anesthesia by aspiration into heparinized syringes from the marrow cavities of the iliac crests on the day of transplant. The protocol for conditioning transplant was approved by the HORCSCT Review Board and Ethics Committee in Shariati Hospital. Before stem cell infusion, all 10 patients received identical RIC regimen with combination of 30 mg/m 2 fludarabin administered i.v. for five consecutive days (days À8 to À4), melphalan 70 mg/m 2 i.v. for two consecutive days (days À3 and À2) and horse antithymocyte globulin (Atgam, Pfizer Inc, New York, NY, USA) 10 mg/kg for four consecutive days (days À4 to À1).
GVHD prophylaxis
Prophylaxis against GVHD was performed via CsA 1.5 mg/kg. daily i.v. starting on day À1 then 3 mg/kg from day þ 7, plus methyl prednisolone 1 mg/kg i.v. starting on day À5 (day À5 to þ 7), then 0.5 mg/kg/day to day þ 14. CsA level was monitored twice weekly (therapeutic range 100-250 ng/ml).
Supportive care
During hospitalization, all patients received the same supportive care. A total of 10 patients were cared for, in a similar isolation room with HEPA filter. Antimicrobial prophylaxis that was used during transplantation period, consisted of acyclovir 750-1500 mg/m 2 /day. It was i.v. started from day À10 to À1 then 1200-2400 mg/m 2 /day. Acyclovir was given as prophylaxis for herpes simplex and VZV. In addition, trimethopim-sulfamethoxazole was started from À10 to À1 then it continued from þ 36 to 2 years after transplant, it was used as Pneumocystis jiroveci prophylaxis. Itraconazole was administrated to prevent fungal infections for 3 months.
All transfused blood products were irradiated before infusion. A total of patients received IVIg 0.5 g/kg every 3 weeks, but during infections it was given weekly. All patients received G-CSF at 5 mg/kg from day þ 8 until PMN counts recovered to 41 Â 10 9 /l. Blood samples from all patients were screened for CMV infection twice weekly. This test was based on quantitative CMV/DNA by PCR or CMV PP65 Ag. Any patient with positive result for CMV was treated with gancyclovir for 21 days, and the treatment was discontinued after the test became negative.
Follow-up
Disease statuses were monitored by flow cytometric detection of CD18-positive leukocytes in peripheral blood of the recipients monthly for 3 months, then followed up every 6 months. Chimerism evaluations (STR technique) were carried out on BM on days þ 15 and þ 30. Chimerism evaluations were also carried out on peripheral WBCs on days þ 60, þ 90, þ 180 and þ 365, respectively then followed up every 6 months.
Definitions LAD-I consists of two subtypes: severe and moderate types. The severity of disease defined by the level of b2-subunit of CD18 expression on leukocytes; In the severe phenotype, which is usually associated with death during childhood, patients have o%1 normal cell surface expression of CD18; whereas in moderate phenotypes (o10% expression) patients have better prognosis and can survive to adulthood. 16, 17 Mixed chimerism is defined by detection of 5-95% donor's HSC, in the recipient's BM or peripheral blood; full chimerism is quantified when 495% donor's HSC is detected in recipient's BM or peripheral blood. [18] [19] [20] Neutrophil engraftment is defined when ANC is 500/mL or greater on 3 consecutive days. Platelet engraftment is defined when the platelet count exceeded 20 Â 10 3 /mL for 3 consecutive days unsupported by platelet transfusion. Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were scored according to standard criteria.
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Results
Patient and donor's characteristics
The median age of patients and donors were 2. 7 years (range: 1-14.7) and 21 years (range: 3-72), respectively. Median count of pre-transplant leukocytosis was 52 000 (range: 18 000-140 000) and median time of umbilical separation was 25 days (range: 15-45). Donor/recipient characteristics and transplant details are summarized in Table 1 /kg, respectively.
Engraftment and chimerism
All LAD-I patients but one were engrafted (90%). The median times to neutrophil and platelet engraftments were 11 days (range, 7-14), and 13 days (range, 10-32), respectively. Engraftment with full chimerism (495%) occurred in six patients. None of these patients had any symptoms of LAD-I disease during a follow-up period. The other three patients had mixed chimerism. At the latest follow-up time point the chimerism rate in two of them was 35%, and in the other one was 15%. These three patients with mixed chimerism feel well right now but a sustained mild leukocytosis exists in all of them.
GVHD and infections
Five out of 9 patients who achieved engraftment, developed aGVHD. Three patients, who developed cGVHD, had a history of prior aGVHD. The details of GVHD reported are specified in Table 2 .
We used same GVHD treatment, including: prednisolone 1 mg/kg/day and CsA as the first line treatment. Two patients who were refractory to first-line treatment were treated with Daclizumab 1 mg/kg. Patients, who developed aGVHD, were successfully treated by the therapeutic approaches mentioned above, except one patient who died during treatment period.
Four patients (44.4%) who developed CMV infection in the post-transplant period had a favorable response to ganciclovir therapy. The median time of treatment with ganciclovir was 25.5 days (range: 21-30).
Outcome
On the whole, the RIC regimen used in treatment of LAD-I patients was particularly well tolerated. The median time of Table 2 .
Discussion
Recent studies have indicated that allogeneic HSCT is the only curative treatment for patients affected by LAD-I.
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Although several articles have been published concerning the subject of transplantation in LAD-I patients, [4] [5] [6] there is no single unified agreement regarding choice of RIC or myeloablative conditioning regimen for treatment of patients. This can be concluded from a small number of patients who underwent transplantation around the world and also different types of conditioning regimens used in different centers. [2] [3] [4] [5] [6] [7] [8] [9] [10] As pre-transplant infections in primary immunodeficiencies patients especially those affected by LAD-I lead to rise in mortality rate, [2] [3] [4] [5] [6] [7] [8] [9] [10] the use of less-toxic RIC as conditioning regimen seems to be highly effected in this regard. On the other hand, as LAD-I patients have hyperactive myeloid macrophage lineage, RIC regimen results in a high incidence of mixed chimerism and rejection in such affected patients. [8] [9] [10] [11] In 2007, the first pediatric transplant unit was established in our center. As all of the patients referred to our center were found to be infected at the time of admission or transplantation, RIC regimen was used as the best treatment option for affected patients. According to the results of the study, RIC regimen is found to be safe and feasible therapeutic approach in the treatment of LAD-I patients. Recipients of RIC transplant, those with either full or mixed chimerism, had a long-term survival rate with no manifestation of LAD-I symptoms. It is also noticeable that the incidence of aGVHD (grades III and IV), was significantly more common among patients in posttransplant period. This is probably because of the use of peripheral blood instead of BM as a stem cell source for transplantation. On the other hand, two patients who developed GVHD grade IV were not fully matched with their donors. 
